A clinical trial of nivolumab, an anti–PD-L1 immune checkpoint inhibitor, for the treatment of metastatic ccRCC (CheckMate-025) has demonstrated that nivolumab has significantly superior OS, hazard ratio, ORR and overall response rate [14]. Here, CD274 is linked to nonpapillary renal cell carcinoma.